Compliance Rate

Compliance Rate 0%
Compliant submissions 0
Incompliant submissions 0
Total trials 0

My Organizations' Clinical Trials

Showing 2275 of 2529 entries
View as:

Study of Pharmacodynamics of LIK066 in Overweight and Obese Women With Polycystic Ovary Syndrome

Phase: N/A Priority: Normal
NCT ID: NCT03152591 Org: User:
Start: 07/24/17 End: 06/25/18 Due: 06/25/19

A 24-week Off-drug Extension Study in Sarcopenic Elderly Who Completed Treatment in the 6-month Core Study

Phase: N/A Priority: Normal
NCT ID: NCT02468674 Org: User:
Start: 07/22/15 End: 12/03/18 Due: 12/03/19

Safety, Tolerability,Pharmacokinetics(PK)and Pharmacodynamics(PD)Assessment of LCQ908 in Patients With Severe Hypertriglyceridemia

Phase: N/A Priority: Normal
NCT ID: NCT01146522 Org: User:
Start: 05/31/10 End: 10/31/11 Due: 10/31/12

Safety of RAD001 in Combination With Cisplatin and Etoposide in Lung Cancer Patients

Phase: N/A Priority: Normal
NCT ID: NCT00466466 Org: User:
Start: 04/30/07 End: - Due: -

Efficacy and Safety of Dex-Methylphenidate Extended Release 30 mg Versus 20 mg in Children (6-12 Years) With Attention-Deficit/Hyperactivity Disorder (ADHD) in a Laboratory Classroom Setting.

Phase: N/A Priority: Normal
NCT ID: NCT00776009 Org: User:
Start: 10/31/08 End: 12/31/08 Due: 12/31/09

Study of Efficacy and Safety of Secukinumab in Subjects With Moderate to Severe Chronic Plaque-type Psoriasis

Phase: N/A Priority: Normal
NCT ID: NCT03066609 Org: User:
Start: 02/28/17 End: 11/20/18 Due: 11/20/19

An Extention Study of Safety of Canakinumab in Japanese Patients With Periodic Fever Syndromes

Phase: N/A Priority: Normal
NCT ID: NCT02911857 Org: User:
Start: 10/03/16 End: 01/27/17 Due: 01/27/18

Canakinumab to Treat Neonatal-Onset Multisystem Inflammatory Disease

Phase: N/A Priority: Normal
NCT ID: NCT00770601 Org: User:
Start: 01/26/09 End: 02/17/11 Due: 02/17/12

Pharmacokinetics of TNO155 in Participants With Mild, Moderate, or Severe Hepatic Impairment Compared to Matched Healthy Participants

Phase: N/A Priority: Normal
NCT ID: NCT05490030 Org: User:
Start: 03/06/25 End: 06/26/25 Due: 06/26/26

Safety and Efficacy of INC280 and Buparlisib (BKM120) in Patients With Recurrent Glioblastoma

Phase: N/A Priority: Normal
NCT ID: NCT01870726 Org: User:
Start: 01/09/14 End: 12/23/16 Due: 12/23/17

Zoledronic Acid Treatment (Every 4 or 12 Weeks) to Prevent Skeletal Complications in Advanced Multiple Myeloma Participants

Phase: N/A Priority: Normal
NCT ID: NCT00622505 Org: User:
Start: 11/07/07 End: 04/03/12 Due: 04/03/13

Study to Evaluate the Impact of a Targeted Lipid Optimization Program on LDL-C Control in At-risk Adult Patients With Dyslipidemia

Phase: N/A Priority: Normal
NCT ID: NCT07034690 Org: User:
Start: 06/30/25 End: 06/30/27 Due: 06/30/28

Study of ECI830 Single Agent or in Combination in Patients With Advanced HR+/HER2- Breast Cancer and Other Advanced Solid Tumors

Phase: N/A Priority: Normal
NCT ID: NCT06726148 Org: User:
Start: 04/03/25 End: 09/25/28 Due: 09/25/29

Lp(a) Lowering Study of Pelacarsen (TQJ230) With Background Inclisiran in Participants With Elevated Lp(a) and Established ASCVD

Phase: N/A Priority: Normal
NCT ID: NCT06813911 Org: User:
Start: 04/30/25 End: 12/01/27 Due: 12/01/28

Efficacy and Safety of Subcutaneous Secukinumab (AIN457) for Moderate to Severe Chronic Plaque-type Psoriasis Assessing Different Doses and Dose Regimens

Phase: N/A Priority: Normal
NCT ID: NCT01406938 Org: User:
Start: 08/31/11 End: 05/31/13 Due: 05/31/14

Study to Assess the Pharmacokinetics, Safety, and Tolerability of Iptacopan in Pediatric PNH Patients

Phase: N/A Priority: Normal
NCT ID: NCT06934967 Org: User:
Start: 07/28/25 End: 10/31/31 Due: 10/31/32

Study of NIS793 and Other Novel Investigational Combinations With SOC Anti-cancer Therapy for the 2L Treatment of mCRC

Phase: N/A Priority: Normal
NCT ID: NCT04952753 Org: User:
Start: 11/15/21 End: 01/20/25 Due: 01/20/26

Efficacy and Safety of Deferasirox in Non-transfusion Dependent Thalassemia Patients With Iron Overload and a One Year Open-label Extension Study

Phase: N/A Priority: Normal
NCT ID: NCT00873041 Org: User:
Start: 11/30/08 End: 06/30/12 Due: 06/30/13

A Phase IV Study to Evaluate Safety, Tolerability and Effectiveness of Rivastigmine Patch 15cm2 in Patients With Severe Dementia of the Alzheimer's Type.

Phase: N/A Priority: Normal
NCT ID: NCT02989402 Org: User:
Start: 12/31/18 End: 12/08/22 Due: 12/08/23

EPO906 Therapy in Patients With Prostate Cancer

Phase: N/A Priority: Normal
NCT ID: NCT00035113 Org: User:
Start: 01/31/02 End: 01/31/04 Due: 01/31/05

A Prospective, Non-interventional Study of JAKAVI® (Ruxolitinib) Treatment in Patients With Polycythemia Vera

Phase: N/A Priority: Normal
NCT ID: NCT05853445 Org: User:
Start: 08/17/15 End: 05/03/23 Due: 05/03/24

Expanded Access Study of RAD001 in Metastatic Renal Cell Cancer Patients Who Are Intolerant of or Who Have Failed Despite Prior Vascular Endothelial Growth Factor Therapy

Phase: N/A Priority: Normal
NCT ID: NCT00655252 Org: User:
Start: - End: - Due: -

Efficacy, Safety and Pharmacokinetics of Artemether-lumefantrine Dispersible Tablet in the Treatment of Malaria in Infants < 5 kg

Phase: N/A Priority: Normal
NCT ID: NCT01619878 Org: User:
Start: 10/31/12 End: 07/31/14 Due: 07/31/15

Study of Quality of Life in Subjects With Chronic or High-frequency Episodic Migraine and Associated Comorbidities Treated With Erenumab

Phase: N/A Priority: Normal
NCT ID: NCT04114630 Org: User:
Start: 10/30/19 End: 01/07/22 Due: 01/07/23

Study of Dovitinib Versus Sorafenib in Patients With Metastatic Renal Cell Carcinoma

Phase: N/A Priority: Normal
NCT ID: NCT01223027 Org: User:
Start: 03/31/11 End: 06/30/14 Due: 06/30/15